Alpha Synuclein and LRRK2 Inhibitors - Novel Drug Candidates for Parkinson's Disease; New Report Launched
The Competitive Intelligence report about Alpha Synuclein and LRRK2 Inhibitors - Novel Drug Candidates for Parkinson's Disease provides a competitor analysis in the discovery and development pipeline of novel therapeutics for treatment of Parkinson's Disease (PD). Alpha-synuclein and leucine-rich repeat kinase 2 (LRRK2) represent molecular targets for novel drug candidates to treat PD. Purchase of the pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the...
View full press release